AMBU B Ambu A/S Class B

Ambu A/S: Malaysian government orders two-week movement control

Ambu A/S: Malaysian government orders two-week movement control

With the rise in Covid-19 cases, the Malaysian government has declared that the entire country will be on a movement control order starting 18 March, 2020 and expected to end on 31 March, 2020. Ambu owns and operates a manufacturing plant in Malaysia where a.o. Ambu’s single-use endoscopes are being manufactured. It is currently uncertain whether this order will also apply to the factory or the factory can be exempt as our aScope is one of the few guaranteed sterile bronchoscopes available if you need to do a bronchoscopy despite the Covid-19 situation.

Even in a situation where the Ambu factory in Malaysia will be subject to the movement control order, we expect to have sufficient inventories of aScope and most other products manufactured at the site to avoid any significant disruption to the supply chain within the duration of the movement order.

Assuming that the movement control order expires as stated on 31 March, 2020, we expect that the impact from the Malaysian government action will not have material impact on our guidance as provided at Q1 on 4 February, 2020.



Contact

Investor relations

Michael Højgaard, CFO, tel. , email:

Nicolai Thomsen, Investor Relations Manager, tel. , email:

Media

Mikkel Trier Wagner, Director Corporate Communications, tel. , email:

Attachment

EN
17/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Ambu AS: 1 director

A director at Ambu AS bought 2,800 shares at 15.412USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK144.00) - Possibly isolated softness

Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch